Health Trials

Malignant Peripheral Nerve Sheath Tumor Mpnst

3

Review clinical trials related to Malignant Peripheral Nerve Sheath Tumor Mpnst. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.

Participants needed: 20
Trial details
Phase: Phase 1, Phase 2Age: 2-21Biological sex: AllType: InterventionalSponsor: USWM CT, LLCUpdated: Feb 9, 2026Locations: 10
Eligibility criteria

Subject has histologically confirmed diagnosis of any one of the following cance... [+5]

Positive for HLA-A*02:05 in either allele; or any A*02 having same protein seque... [+8]

Read more
Status: Recruiting

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore the efficacy and safety.

Participants needed: 45
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Fudan UniversityUpdated: Jan 8, 2026Locations: 1
Eligibility criteria

Age 18 to 75 years, regardless of gender; [+7]

Previous treatment for advanced soft tissue sarcoma, except for those who relaps... [+13]

Read more
Status: Not yet recruiting

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors

Participants needed: 45
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: AeRang KimUpdated: Jul 3, 2025Locations: 1
Eligibility criteria

AGE: Part A and C: ≥ 18 years of age AGE: Part B: ≥12 years (minimum BSA ≥0.55m2... [+28]

A malignancy treated with curative intent and with no known active disease ≥2 ye... [+36]

Read more